- Home
- FROG vs LEGN Comparison
FROG vs LEGN Comparison
Compare FROG & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FROG
- LEGN
- Stock Information
- Founded
- FROG 2008
- LEGN 2014
- Country
- FROG United States
- LEGN United States
- Employees
- FROG N/A
- LEGN N/A
- Industry
- FROG Computer Software: Prepackaged Software
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- FROG Technology
- LEGN Health Care
- Exchange
- FROG Nasdaq
- LEGN Nasdaq
- Market Cap
- FROG 4.8B
- LEGN 5.4B
- IPO Year
- FROG 2020
- LEGN 2020
- Fundamental
- Price
- FROG $47.50
- LEGN $34.60
- Analyst Decision
- FROG Strong Buy
- LEGN Strong Buy
- Analyst Count
- FROG 18
- LEGN 11
- Target Price
- FROG $45.11
- LEGN $74.10
- AVG Volume (30 Days)
- FROG 1.7M
- LEGN 1.0M
- Earning Date
- FROG 08-07-2025
- LEGN 08-11-2025
- Dividend Yield
- FROG N/A
- LEGN N/A
- EPS Growth
- FROG N/A
- LEGN N/A
- EPS
- FROG N/A
- LEGN N/A
- Revenue
- FROG $474,761,000.00
- LEGN $796,838,000.00
- Revenue This Year
- FROG $19.78
- LEGN $70.75
- Revenue Next Year
- FROG $15.42
- LEGN $52.47
- P/E Ratio
- FROG N/A
- LEGN N/A
- Revenue Growth
- FROG 21.97
- LEGN 74.75
- 52 Week Low
- FROG $26.10
- LEGN $27.34
- 52 Week High
- FROG $47.98
- LEGN $59.62
- Technical
- Relative Strength Index (RSI)
- FROG 64.43
- LEGN 31.32
- Support Level
- FROG $43.73
- LEGN $35.10
- Resistance Level
- FROG $45.44
- LEGN $36.80
- Average True Range (ATR)
- FROG 2.30
- LEGN 1.34
- MACD
- FROG 0.51
- LEGN -0.39
- Stochastic Oscillator
- FROG 95.55
- LEGN 0.26
About FROG JFrog Ltd.
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from Israel and also has its presence in United States, India and other regions.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.